Eventide Healthcare & Life Sciences Fd Cl I
ETIHX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- Willow Grove, PA19090 Boston MA United States of America 02110
- IPO Date
- Dec 27, 2012
- CIK
- 0001355064
- Website
- morganstanley.com
- Similar Companies
- Business
- Eventide Healthcare & Life Sciences Fund Class I (ETIHX) is an open-end mutual fund that seeks long-term capital appreciation by investing at least 80% of its net assets in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stocks, preferred stocks, convertible debt, and options; it concentrates at least 25% of its investments in drug-related industries such as biotechnology, pharmaceuticals, and therapeutics for unmet medical needs, rare and orphan diseases, pulmonary infections, neuromuscular disorders, obesity, neurological and psychiatric conditions, autoimmune diseases, oncology, and cardiac arrhythmias. The fund targets early development-stage companies with a median market capitalization of $2.4 billion as of September 30, 2025, and provides access to unique offerings including initial public offerings, mezzanine financings, and up to 15% in private investments; top holdings as of the latest reporting include Insmed Inc. (therapies for pulmonary infections), Mirum Pharmaceuticals Inc. (rare pediatric cholestasis treatments), Guardant Health Inc. (cancer cell diagnostics), Celcuity Inc. (novel drugs for breast and prostate cancer), and Scholar Rock Holding Corp. (therapeutics for neuromuscular disorders). Primarily serving institutional investors with a minimum initial investment of $100,000, the fund maintains total net assets of approximately $1.50 billion, a net expense ratio of 1.32%, and benchmarks performance against the S&P Biotechnology Select Industry Index. Launched on December 27, 2012, and domiciled in the United States, the fund operates with a focus on small-cap growth stocks in the health sector, with 93.56% allocation to healthcare, 88.26% to U.S. stocks, and minor exposure to non-U.S. stocks (6.78%, including the United Kingdom) and cash (3.05%); it is available for sale in the United States. Eventide Asset Management, LLC serves as the investment adviser, with headquarters in Boston, Massachusetts. Recent changes include the appointment of I-hung Shih, PhD, as co-portfolio manager effective September 1, 2024, alongside lead portfolio manager Finny Kuruvilla, MD, PhD, who has managed the fund since inception; this complements Dr. Shih's prior roles at Wellington Management and T. Rowe Price in biotech investments. The fund's portfolio underwent updates reflecting strong performance in holdings like Verona Pharma PLC (up 293.30% over one year) and Scholar Rock (up 265.66%), contributing to year-to-date returns of 39.06% as of November 13, 2025. Eventide Asset Management expanded its offerings with the launch of three new systematic ETFs (ESLG, ESLV, ESSC) on September 30, 2025, signaling broader strategic growth in active and thematic investment strategies.